In a study of 4,000 participants, the vaccine showed efficacy of 85.3 percent 14 to 28 days after a booster vaccination.
China has approved its first domestically developed mRNA vaccine against COVID-19, its manufacturer said on Wednesday, months after the relaxation of strict zero-COVID regulations sparked a surge in cases.
The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for “emergency use” by Beijing’s health regulator, the company said in a statement on Wednesday.
It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details.
China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.
While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body’s cells how to produce a protein – in this case, the spike protein on the coronavirus that causes COVID.
The body’s immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus invades.